Xarelto Gastrointestinal Bleeding

Xarelto Bleeding
Patients who use the blood thinner Xarelto may be at risk for gastrointestinal bleeding for which there is no approved reversal agent. A growing number of Xarelto lawsuits accuse the drug’s manufacturers of failing to provide patients and doctors with appropriate warnings regarding this and other forms of internal bleeding associated with use of the drug.

Xarelto Legal Reviews

The nationwide law firm of Bernstein Liebhard LLP is already representing plaintiffs who claim to have been harmed by Xarelto. To learn more about the legal options available to alleged victims of Xarelto gastrointestinal bleeding, please contact our Firm at (888) 994-5118.

Xarelto and Internal Bleeding

Like any blood thinner, Xarelto can sometimes cause serious internal bleeding. However, there currently exists no approved antidote to reverse Xarelto’s anticoagulant effect should internal hemorrhaging occur. As such, a seemingly-minor trauma can become a life-threatening medical emergency for a Xarelto patient.

Symptoms of Xarelto Gastrointestinal Bleeding

Gastrointestinal bleeding encompasses any hemorrhaging that occurs within the intestinal tract, including the esophagus, stomach, upper intestine, lower intestine (colon), bowel, rectum, and anus. Because any internal bleeding associated with the use of Xarelto is potentially serious, patients should seek medical help if they experience any of the following:

  • Blood in vomit
  • Vomit that has the appearance of coffee grounds
  • Black, tarry stools
  • Blood in the stool that increases over time
  • Abdominal pain
  • Weakness
  • Light headedness
  • Shortness of breath
  • Light headedness

Xarelto Gastrointestinal Bleeding Report and Studies

  • 2011: The ROCKET AF clinical trial found that gastrointestinal bleeding occurred in 3.1% of Xarelto patients, vs. 2% of warfarin patients. The ROCKET AF clinical trial played an important role in Xarelto’s regulatory approval, both in the U.S. and abroad.
  • 2015: A study published in the British Medical Journal suggests that people who take Xarelto may be twice as likely to suffer from gastrointestinal bleeding compared to those who use warfarin. Read More

Xarelto Lawsuit Allegations

Thousands of plaintiffs have filed Xarelto lawsuits after allegedly suffering serious episodes of internal bleeding while using the medication. These lawsuits allege that the drug’s manufacturers:

  • Failed to provide appropriate warnings about the risk of Xarelto bleeding and related complications
  • Withheld information about the lack of an approved agent to revers Xarelto bleeding events
  • Utilized aggressive marketing tactics to induce physicians to prescribe the more expensive and more dangerous drug;
  • Sold an unreasonably dangerous and defective drug as it was initially formulated
  • Failed to update warnings or otherwise warn the public that a large number of Xarelto patients were suffering severe and life-threatening injuries from uncontrollable bleeding events

Xarelto Litigation Update

  • January 2016: The federal Xarelto litigation convened a Status Conference on January 22nd, at which time it scheduled Oral Arguments for February 23rd regarding  a proposed order governing the parties’ interactions with plaintiffs’ prescribing and treating physicians. It was also noted that the parties exchanged bellwether trial selections on January 11th, while random selections were made on January 15th. Read More
  • December 2015: The federal Xarelto litigation has begun the process of selecting lawsuits for its first four bellwether trials. The first two trials will get underway in the U.S. District Court, Eastern District of Louisiana, on February 6, 2017 and March 13, 2017. The third and fourth will take place in yet-to-be determined Districts in Mississippi and Texas on April 24, 2017 and May 30, 2017. Read More
  • April 2015: The federal Xarelto litigation will hold its “Science Day” on June 28th, 2015.Read More
  • December 2014: The U.S. Judicial Panel on Multidistrict Litigation (JPML) has agreed to create a multidistrict litigation for federally-filed Xarelto bleeding claims in the U.S. District Court, Eastern District of Louisiana. Read More
  • October 2014: Six Plaintiffs in Xarelto lawsuits file a motion seeking centralization of all such federal claims in a single court for the purposes of coordinated pretrial proceedings. Read More

Legal Help for Victims of Xarelto Gastrointestinal Bleeding

The defective drug attorneys at Bernstein Liebhard LLP are providing free, no-obligation legal reviews to alleged victims of Xarelto-related gastrointestinal bleeding. To obtain your case review, please call (888) 994-5118.

  1. Xarelto (rivaroxaban) U.S. Food and Drug Administration (November 2012) http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm326654.htm
  2. NEJM (2011) “Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation” http://www.nejm.org/doi/full/10.1056/NEJMoa1009638
  3. BMJ (2015) “Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study” http://www.bmj.com/content/350/bmj.h1585
Last Modified: February 23, 2016

Get the latest news and litigation updates about this case by following us on Facebook. Click the "Like" button below.

 
 
 

Follow Us

RXInjuryHelp.com on Google+  RXInjuryHelp.com on Facebook  RXInjuryHelp.com on LinkedIn  RXInjuryHelp.com on Twitter  RXInjuryHelp.com on YouTube  RXInjuryHelp.com on Pinterest